Serono to raise up to $2 billion in US listing:
This article was originally published in Clinica
Swiss company Serono plans to list on the New York Stock Exchange to raise up to $2 billion. The company, which is mainly a pharmaceutical concern, is present in diagnostics through its Geref Diagnostic product. This tests the ability of the somatroph of the pituitary gland to secrete growth hormone, in paediatric growth hormone deficiency.